Feb. 12, 2024 Price forecast | 2 weeks: -2.46% | 1 month: -4.87% | 3 months: -8.91%


RARE stock forecast

Our latest prediction for Ultragenyx Pharmaceutical Inc.'s stock price was made on the Feb. 12, 2024 when the stock price was at 46.74$.

In the short term (2weeks), RARE's stock price should underperform the market by -2.46%. During that period the price should oscillate between -11.20% and +5.53%.

In the medium term (3months), RARE's stock price should underperform the market by -8.91%. During that period the price should oscillate between -29.53% and +12.48%.

Create a solid portfolio with RARE

Add RARE to your portfolio and optimize it!


About Ultragenyx Pharmaceutical Inc.

ultragenyx is a clinical-stage biotechnology company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies. our company is led by an experienced management team in rare disease therapeutics. recognizing that our primary responsibility is to our patients, we are working with advocacy groups to provide support and outreach to individuals and families affected by these disorders and engage them in the clinical testing process. we are also working with regulatory agencies to design and conduct high quality clinical studies that meet the requirements for approval. we are creating an improved model for successful rare disease d

At the moment the company doesn't generate any revenue.

On its last earning announcement, the company reported a loss of -10.31$ per share.

The book value per share is 14.03$

Ultragenyx Pharmaceutical Inc. website


Three months stock forecastFeb. 12, 2024


Financials

Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
- - -592M - -635M -10.31 - - 72M 14.03 - - -